![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Harbeck, N. 
ORCID: https://orcid.org/0000-0002-9744-7372; Modi, S.; Pusztai, L.; Ohno, S.; Wu, J.; Kim, S.-B.; Yoshida, A.; Fabi, A.; Cao, X.; Joseph, R.; Li, R.; Żurawski, B.; Escrivá-de-Romaní, S. ORCID: https://orcid.org/0000-0001-7816-7589; Meneguetti, R.; Supavavej, A.; Chen, S.-C.; Liu, Z.; Kelly, C.; Curigliano, G. ORCID: https://orcid.org/0000-0003-1781-2518; Symmans, W.F. ORCID: https://orcid.org/0000-0002-1526-184X; Gufran, M.; Ke, J.; Konpa, A.; Herbolsheimer, P. und Boileau, J.-F.
(2025):
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
In: Annals of Oncology [Forthcoming]
ORCID: https://orcid.org/0000-0002-9744-7372; Modi, S.; Pusztai, L.; Ohno, S.; Wu, J.; Kim, S.-B.; Yoshida, A.; Fabi, A.; Cao, X.; Joseph, R.; Li, R.; Żurawski, B.; Escrivá-de-Romaní, S. ORCID: https://orcid.org/0000-0001-7816-7589; Meneguetti, R.; Supavavej, A.; Chen, S.-C.; Liu, Z.; Kelly, C.; Curigliano, G. ORCID: https://orcid.org/0000-0003-1781-2518; Symmans, W.F. ORCID: https://orcid.org/0000-0002-1526-184X; Gufran, M.; Ke, J.; Konpa, A.; Herbolsheimer, P. und Boileau, J.-F.
(2025):
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
In: Annals of Oncology [Forthcoming]
Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Andersen, J.; Patt, D.; Danso, M.; Ferreira, M.; Mouret-Reynier, M.-A.; Im, S.-A.; Ahn, J.-H.; Gion, M.; Baron-Hay, S.; Boileau, J.-F.; Ding, Y.; Tryfonidis, K.; Aktan, G.; Karantza, V. und O'Shaughnessy, J.
(2022):
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
In: New England Journal of Medicine, Bd. 386, Nr. 6: S. 556-567